Zahin Shahriar

Dr. Zahin Shahriar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
Zahin ShahriarZahin Shahriar
Zahin Shahriar
MKMaliha Khalid
Maliha Khalid
NZNafila Zeeshan
Nafila Zeeshan
RARaheel Ahmed
Raheel Ahmed

22 January 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
NZNafila Zeeshan
Nafila Zeeshan
MFMohammad Rayyan Faisal
Mohammad Rayyan Faisal
KPKrish Patel
Krish Patel
KAKhaled Ali
Khaled Ali
Background: Aortic Dissection (AD) is a life-threatening condition and one of the major causes of death in the U.S. Despite its clinical significance, trends in AD related mortality remain understudied. We aim to analyze nationwide mortality trends in AD in the U.S. Methods: Data from CDC WONDER (1999–2024) identified U.S mortality rates in adults aged ≥ 25 years with AD (ICD-10: I71.0). Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 were calculated. Trends were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Results: From 1999 to 2024, a total of 115,449 deaths from AD were recorded. The AAMR increased from 2.1 in 1999 to 2.4 in 2024 (AAPC of 0.46; 95% CI: 0.31 to 0.61; p < 0.001). Men had higher mortality than women (Overall AAMR: 2.62; p < 0.001 vs. 1.45; p < 0.001) (AAPC: 0.22; 95% CI: 0.05 to 0.39 vs. 0.61; 95% CI: 0.42 to 0.83) respectively. Racially, non-Hispanic (NH) Blacks demonstrated the greatest overall AAMR of 3.11. Regionally, AAMRs were highest in the Midwest (2.17) followed by the West (2.14). The urban areas had higher overall AAMRs than the rural areas (1.95, p = 0.27 vs. 1.90, p = 0.074). The majority of deaths occurred in medical facilities (88,976 deaths, 77.06%) and in older adults with CMR (5.8). Conclusion: Mortality trends in AD increased from 1999 to 2024. Higher trends occurred in men, urban areas, Midwest region, NH Black population and medical facilities.

9 November 2025 in ASIDE Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
AGAnika Goel
Anika Goel
MHMirna Hussein
Mirna Hussein
KPKrish Patel
Krish Patel
RARaheel Ahmed
Raheel Ahmed
Introduction: Angina is one of the ischemic heart diseases (IHD) that contributes to major cardiovascular complications up to death. We aim to assess angina-related mortality among adults aged ≥65 years in the U.S. Methods: Nationwide mortality records were obtained from the CDC-WONDER database from 1999 to 2023 among U.S. adults aged ≥65 with angina. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population. Joinpoint regression analysis was utilized to evaluate average annual percent changes (AAPCs). Results: From 1999 to 2023, a total of 36,544 deaths occurred among the elderly with angina in the U.S. The overall AAMR per 100,000 decreased from 7.52 in 1999 to 3.73 in 2023 (AAPC of -3.18; 95%CI: -3.79 to -2.75; p < 0.001). The AAMR for men decreased from 8.22 in 1999 to 4.75 in 2023 (AAPC of -2.53%; 95%CI: -3.02 to -2.09), and for women decreased from 6.95 in 1999 to 3.02 in 2023 (AAPC: -3.55%; 95%CI: -4.12 to -3.09). Across racial/ethnic groups, the highest overall rates were observed among NH-White individuals, 3.56. Overall, AAMRs were highest in the West, 4.00. The majority of deaths occurred in medical facilities (40.19%). Between 1999 and 2020, rural areas had a higher overall AAMR of 4.37 compared to urban areas, which had a rate of 3.02. Conclusion: Trends in angina-related mortality declined from 1999 to 2023. Higher mortality rates were observed in men, rural areas, the West region, and among NH White individuals. Our findings indicated that these categories require targeted interventions to reduce mortality.

14 September 2025 in ASIDE Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMohamed Fawzi Hemida
Mohamed Fawzi Hemida
AKAyesha Khan
Ayesha Khan
AMAlyaa Ahmed Ahmed Ibrahim Mohamed
Alyaa Ahmed Ahmed Ibrahim Mohamed
AGAnika Goel
Anika Goel
KPKrish Patel
Krish Patel
ABAhmed Bahnasy
Ahmed Bahnasy
Introduction: Leukemia and ischemic heart disease (IHD) are major U.S. mortality causes. This study analyzes national mortality trends from 1999 to 2020 to assess the impact of public health efforts in leukemia-associated IHD mortality rates.Methods: This retrospective study analyzed death certificate data from the CDC-WONDER database spanning 1999 to 2020, focusing on leukemia (ICD-10: C91–C95) and ischemic heart disease (ICD-10: I20–I25) as multiple causes of mortality in the U.S. population. Crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 100,000 population were calculated. JoinPoint analysis was performed to estimate annual percent change (APC) and average annual percent change (AAPC).Results: From 1999 to 2020, there were 53,603 deaths from combined leukemia and ischemic heart disease among U.S. adults aged 25+, with the AAMR declining from 1.39 to 1.09 per 100,000 (AAPC= -1.30%; 95% CI: -1.90 to -0.68; P= 0.000034). A significant decrease occurred from 1999 to 2018 (AAMR: 1.39 to 0.95; APC= -2.1894%; 95% CI: -2.3995 to -1.9788, P < 0.000001), followed by a period where the trend shifted upward which is statistically significant for the certain subgroups, except men and older adults. Men had higher AAMR than women (1.87 vs. 0.62). Regional AAMRs were highest in the Midwest (1.3). Non-Hispanic Whites had the highest AAMR (1.25). Adults 65+ had a CMR of 5.27 vs. 0.26 for ages 45–64.Conclusion: Significant health disparities exist, as mortality from combined leukemia and IHD is highest among men, older adults, rural populations, and non-Hispanic White individuals.

29 December 2025 in Clinical Cardiology
Verified
Journal Article
Open access
YÖYasin Özen
Yasin Özen
MOMustafa Bilal Ozbay
Mustafa Bilal Ozbay
Zahin ShahriarZahin Shahriar
Zahin Shahriar
HTHüseyin TEZCAN
Hüseyin TEZCAN
ATAbdullah Tuncez
Abdullah Tuncez
BÖBülent Özbay
Bülent Özbay
Background: Naples Prognostic Score (NPS), a composite index incorporating inflammatory and nutritional markers, has emerged as a potential prognostic tool in various cardiovascular conditions; however, no meta‐analysis has yet pooled the available evidence to comprehensively assess its prognostic utility. Objectives: To evaluate the association of NPS with clinical outcomes, including all‐cause mortality, in‐hospital mortality, no‐reflow (NR) phenomenon, and left ventricular ejection fraction (LVEF), in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Methods: MEDLINE, Cochrane, and EMBASE databases were searched for studies comparing high and low NPS groups in ACS patients undergoing PCI. Random‐effects models were used to pool risk ratios (RR) for binary outcomes and mean differences (MD) for continuous outcomes. Heterogeneity was assessed with I² statistics. Statistical analyses were performed using Review Manager 5.4, and R, version 4.2.2. Results: We included seven studies comprising 13 268 patients, with 5628 (42.4%) patients in the low NPS group. Low NPS was significantly associated with decreased all‐cause mortality (RR: 0.42; 95% CI: 0.32–0.55; I² = 48%) and decreased incidence of NR (RR: 0.60; 95% CI: 0.40–0.88; I² = 83%). Patients with low NPS also had higher LVEF (MD: −2.69%; 95% CI: −3.41 to −1.97; I² = 99%). No significant difference was observed in in‐hospital mortality (RR: 0.54; 95% CI: 0.28–1.05; I² = 94%). Conclusion: In ACS patients undergoing PCI, elevated NPS was associated with worse clinical outcomes. These findings support the use of NPS as a practical, biomarker‐based tool for risk stratification in this population.

10 November 2025 in JGH Open
Verified
Journal Article
Open access
MBMuhammad Imaz Bhatti
Muhammad Imaz Bhatti
MSMuhammad Safiullah
Muhammad Safiullah
AIAzka Ijaz
Azka Ijaz
QMQasim Mehmood
Qasim Mehmood
ISIshmal Fatima Shahid
Ishmal Fatima Shahid
Zahin ShahriarZahin Shahriar
Zahin Shahriar
Purpose: Proton pump inhibitors (PPIs) remain the standard treatment option for erosive esophagitis (EE) but have notable limitations due to side effects associated with long‐term use. Tegoprazan, a novel potassium‐competitive acid suppressant (P‐CAB), may provide an alternative treatment option. In this study, we aim to evaluate the healing rates of EE using tegoprazan versus PPIs, along with their respective safety profiles. Methods: A comprehensive literature search was conducted in PubMed, Embase, and ClinicalTrials.gov from inception to March 2025. Risk of bias was evaluated using the Cochrane RoB 2.0 tool. Pooled estimates were calculated using random‐effects models in Review Manager 5.4. Results: Three RCTs encompassing a total of 766 patients were included in the analysis. Tegoprazan demonstrated comparable healing rates to PPIs at both 4 weeks (risk ratio [RR] 1.05; 95% confidence interval [CI]: 0.99–1.11; p = 0.12) and 8 weeks (RR 1.02; 95% CI: 0.98–1.06; p = 0.35). Subgroup analyses by dose (50 and 100 mg) showed no significant differences. While overall adverse event rates were similar between groups, the incidence of headache was numerically lower in the tegoprazan group (1.3% vs. 4.2%; RR = 0.40; 95% CI: 0.08–2.00; p = 0.26), though this difference was not statistically significant. Conclusion: Tegoprazan shows comparable efficacy and safety to standard PPIs for treating EE. While healing rates were slightly higher, particularly with the 100 mg dose, the differences were not statistically significant. Tegoprazan may be a suitable alternative for patients intolerant to PPIs, though larger, long‐term, multiethnic studies are warranted to confirm these findings and assess patient‐centered outcomes.